Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effects of MIND Diet on Brain Fog, Stress, and Sleep Quality in Young Adults (Young Mind)

19. November 2026 aktualisiert von: Halic University

The Effect of a MIND Diet-Based Nutritional Intervention on Brain Fog, Perceived Stress, Sleep Quality, and Selected Biochemical Findings in Young Adults

This study aims to evaluate the effects of a MIND diet-based nutritional intervention on brain fog, perceived stress, sleep quality, and selected biochemical parameters in young adults. It will also compare the effects of the MIND diet with those of the Mediterranean diet and usual dietary habits.

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) is a dietary pattern that combines elements of the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets. It emphasizes the consumption of green leafy vegetables, other vegetables, berries, nuts, whole grains, legumes, fish, poultry, and olive oil, while limiting foods high in saturated fat, processed foods, and sweets. The Mediterranean diet similarly emphasizes plant-based foods, olive oil, whole grains, legumes, vegetables, fruits, nuts, and fish.

Young adults aged 18-35 years who meet the study eligibility criteria will be included. Participants will be randomly assigned to one of three groups: a MIND diet intervention group, a Mediterranean diet intervention group, or a control group.

Participants in the MIND diet group will receive nutritional guidance and follow a MIND diet-based dietary plan for 12 weeks. Participants in the Mediterranean diet group will receive nutritional guidance and follow a Mediterranean diet-based dietary plan for the same period. Participants in the control group will continue their usual dietary habits without receiving a structured dietary intervention during the study period.

Assessments will be conducted at baseline and at the end of the 12-week intervention. These assessments will include brain fog, perceived stress, sleep quality, dietary intake, and anthropometric measurements. Brain fog, perceived stress, and sleep quality will be evaluated using standardized assessment questionnaires. Dietary intake and adherence to the assigned dietary patterns will also be monitored throughout the intervention.

Selected biochemical parameters, including fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, liver enzymes, uric acid, urea, and creatinine, will be assessed through blood samples.

The study will investigate whether following the MIND or Mediterranean dietary pattern for 12 weeks is associated with changes in brain fog, perceived stress, sleep quality, and selected biochemical parameters in young adults. The findings may contribute to a better understanding of the relationship between dietary patterns and cognitive, psychological, sleep-related, and metabolic health.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

### Detailed Description

The MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet is a dietary pattern developed by combining elements of the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH) diet. It emphasizes foods that may support brain and metabolic health, including green leafy vegetables, other vegetables, berries, nuts, whole grains, legumes, fish, and poultry, while limiting the consumption of foods high in saturated fat, processed foods, sweets, and fried foods.

The Mediterranean diet is characterized by a high intake of vegetables, fruits, legumes, whole grains, nuts, seeds, and olive oil, with regular consumption of fish and moderate consumption of other animal-based foods. Both dietary patterns emphasize minimally processed, nutrient-dense foods and a balanced dietary approach.

This study is designed as a 12-week, randomized, parallel-group, three-arm interventional trial involving young adults aged 18-35 years. The study will compare the effects of a MIND diet-based nutritional intervention and a Mediterranean diet-based nutritional intervention with a control group that will maintain its usual dietary habits.

Participants assigned to the MIND diet group will receive individualized nutritional counseling and a dietary plan based on MIND diet principles. The intervention will emphasize the regular consumption of green leafy vegetables, other vegetables, berries, nuts, legumes, whole grains, fish, and poultry, while encouraging the limitation of foods associated with lower adherence to the MIND dietary pattern.

Participants assigned to the Mediterranean diet group will receive individualized nutritional counseling and a dietary plan based on Mediterranean diet principles. The intervention will emphasize vegetables, fruits, legumes, whole grains, olive oil, nuts, seeds, and fish as important components of daily and weekly food consumption.

Dietary plans will be individualized according to participants' age, sex, physical activity level, and estimated energy requirements. Participants in both intervention groups will receive nutritional guidance throughout the 12-week study period. Dietary adherence and food consumption will be monitored at 15-day intervals using dietary records, including three-day food consumption records, and adherence assessments.

Participants in the control group will not receive a structured dietary intervention and will be asked to maintain their usual dietary habits during the study period.

Baseline assessments will be performed before the dietary interventions begin. At the end of the 12-week intervention, the assessments will be repeated to evaluate changes over time.

The primary areas of assessment include brain fog, perceived stress, and sleep quality. Brain fog will be assessed using the Brain Fog Scale, perceived stress using the Perceived Stress Scale (PSS-10), and sleep quality using the Pittsburgh Sleep Quality Index (PSQI).

Anthropometric and body composition measurements will also be obtained, including body weight, height, body mass index (BMI), and body composition assessed by bioelectrical impedance analysis.

Fasting blood samples will be collected to evaluate selected biochemical parameters, including fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid, urea, and creatinine.

The study aims to determine whether a 12-week MIND diet-based or Mediterranean diet-based nutritional intervention is associated with changes in brain fog, perceived stress, sleep quality, anthropometric measurements, and selected biochemical parameters in young adults. Comparisons between the three study groups will be used to evaluate the potential effects of the dietary interventions.

Studientyp

Interventionell

Einschreibung (Geschätzt)

42

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 35 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults aged 18-35 years.
  • Willingness to participate in the study and provide written informed consent.
  • Ability and willingness to follow the assigned dietary intervention for 12 weeks.
  • Ability to complete dietary records and study questionnaires.

Exclusion Criteria:

  • Presence of chronic diseases requiring a specific medical nutrition therapy.
  • Pregnancy or breastfeeding.
  • Food allergies or intolerances that prevent adherence to the study diets.
  • Following a medically prescribed or restrictive diet.
  • Regular use of medications that may significantly affect the study outcomes.
  • Any condition that may interfere with participation in the study or adherence to the intervention.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Mind Diet Group

Participants will receive a 12-week dietary intervention based on the MIND diet.

Participants will receive a 12-week dietary intervention based on the MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet. The intervention will include individualized dietary guidance, regular nutritional counseling, dietary monitoring, and adherence assessments throughout the study period.

Experimental: Mediterranean Diet Group

Participants will receive a 12-week dietary intervention based on the Mediterranean diet.

Participants will receive a 12-week dietary intervention based on the Mediterranean diet. The intervention will include individualized dietary guidance, regular nutritional counseling, dietary monitoring, and adherence assessments throughout the study period.

Kein Eingriff: Control Group

Participants will not receive a specific dietary intervention during the 12-week study period.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Brain Fog Scale Score
Zeitfenster: 12 weeks

Brain fog will be assessed using the 23-item Brain Fog Scale. The total score ranges from 0 to 92. Higher scores indicate more severe brain fog symptoms and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Pittsburgh Sleep Quality Index Scores
Zeitfenster: 12 weeks

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21. Higher scores indicate poorer sleep quality and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks
Change in Perceived Stress Scores
Zeitfenster: 12 weeks

Perceived stress will be assessed using the 10-item Perceived Stress Scale (PSS-10). The total score ranges from 0 to 40. Higher scores indicate higher levels of perceived stress and a worse outcome. Changes in total scores between baseline and Week 12 will be evaluated.

12 weeks
Change in Fasting Blood Glucose Levels
Zeitfenster: 12 weeks

Fasting blood glucose levels will be measured using standard biochemical laboratory methods after overnight fasting. Changes in fasting blood glucose levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Total Cholesterol Levels
Zeitfenster: 12 weeks

Serum total cholesterol levels will be measured using standard biochemical laboratory methods. Changes in total cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Low-Density Lipoprotein (LDL) Cholesterol Levels
Zeitfenster: 12 weeks

Serum low-density lipoprotein (LDL) cholesterol levels will be measured using standard biochemical laboratory methods. Changes in LDL cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in High-Density Lipoprotein (HDL) Cholesterol Levels
Zeitfenster: 12 weeks

Serum high-density lipoprotein (HDL) cholesterol levels will be measured using standard biochemical laboratory methods. Changes in HDL cholesterol levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Triglyceride Levels
Zeitfenster: 12 weeks

Serum triglyceride levels will be measured using standard biochemical laboratory methods. Changes in triglyceride levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Aspartate Aminotransferase (AST) Levels
Zeitfenster: 12 weeks

Serum aspartate aminotransferase (AST) levels will be measured using standard biochemical laboratory methods. Changes in AST levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Alanine Aminotransferase (ALT) Levels
Zeitfenster: 12 weeks

Serum alanine aminotransferase (ALT) levels will be measured using standard biochemical laboratory methods. Changes in ALT levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Uric Acid Levels
Zeitfenster: 12 weeks

Serum uric acid levels will be measured using standard biochemical laboratory methods. Changes in serum uric acid levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Urea Levels
Zeitfenster: 12 weeks

Serum urea levels will be measured using standard biochemical laboratory methods. Changes in serum urea levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks
Change in Serum Creatinine Levels
Zeitfenster: 12 weeks

Serum creatinine levels will be measured using standard biochemical laboratory methods. Changes in serum creatinine levels between baseline and the end of the 12-week intervention will be evaluated.

12 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Ahmet Murat Günal, PhD, Haliç University
  • Hauptermittler: Murat Baş, PhD, Acibadem University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Dezember 2026

Primärer Abschluss (Geschätzt)

1. März 2027

Studienabschluss (Geschätzt)

1. Juni 2027

Studienanmeldedaten

Zuerst eingereicht

6. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

19. November 2026

Zuerst gepostet (Tatsächlich)

20. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • g5wmafbp

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data will not be shared with other researchers due to privacy and confidentiality considerations. Data will be used solely for the purposes of this study and will be handled in accordance with applicable data protection regulations.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .